background
previou
studi
suggest
drug
price
adjust
allow
physician
taiwan
gain
greater
profit
prescrib
gener
drug
better
understand
effect
price
adjust
physician
choic
studi
use
reninangiotensin
drug
includ
angiotensinconvert
enzym
inhibitor
acei
angiotensin
receptor
blocker
arb
examin
impact
price
adjust
util
expenditur
patent
offpat
drug
therapeut
indic
method
use
taiwan
longitudin
health
insur
databas
identifi
patient
receiv
acei
andor
arb
annual
incid
preval
user
acei
arb
overal
reninangiotensin
drug
examin
boxtiao
intervent
analysi
appli
assess
impact
price
adjust
monthli
util
expenditur
drug
acei
divid
patent
offpat
drug
offpat
acei
divid
origin
brand
gener
subgroup
analys
perform
result
number
incid
reninangiotensin
drug
user
decreas
studi
period
number
preval
arb
user
increas
exceed
cumul
number
firsttim
reninangiotensin
drug
user
start
arb
impli
patient
switch
acei
arb
price
adjust
long
term
trend
increas
util
observ
patent
acei
arb
longterm
trend
decreas
observ
offpat
acei
longterm
trend
chang
signific
overal
reninangiotensin
drug
signific
longterm
trend
increas
expenditur
observ
patent
acei
price
adjust
p
arb
price
adjust
p
p
signific
longterm
trend
decreas
expenditur
observ
offpat
acei
price
adjust
p
expenditur
overal
reninangiotensin
drug
show
longterm
trend
increas
price
adjust
p
p
conclus
price
adjust
achiev
longterm
cost
save
overal
reninangiotensin
drug
possibl
switch
acei
arb
within
individu
evid
polici
maker
reconsid
appropri
current
adjust
strategi
appli
patent
offpat
drug
taiwan
nation
health
insur
nhi
system
governmentrun
singlepay
compulsori
program
implement
march
bureau
nation
health
insur
bnhi
execut
organ
nhi
program
program
univers
coverag
includ
pharmaceut
ambulatori
care
inpati
care
tradit
chines
medicin
dental
servic
child
deliveri
rehabilit
home
nurs
care
chronic
psychiatr
rehabilit
current
cover
popul
approxim
million
peopl
three
main
compon
nhi
system
bnhi
insur
bnhicontract
health
care
provid
fund
bnhi
come
insur
employ
govern
bnhi
issu
insur
card
insur
pay
health
care
provid
accord
servic
provid
includ
prescript
list
pharmaceut
benefit
scheme
pb
insur
receiv
medic
servic
bnhicontract
health
care
provid
pay
provid
registr
fee
well
copay
outpati
servic
inpati
servic
drug
bnhi
establish
pb
contain
reimburs
principl
list
reimburs
product
brandspecif
reimburs
price
product
reimburs
price
paid
physician
respons
purchas
prescrib
dispens
taiwan
howev
physician
purchas
medic
pharmaceut
compani
market
trade
price
discount
pb
reimburs
price
profit
margin
physician
develop
differ
reimburs
price
market
trade
price
known
drug
price
deviat
figur
provid
exampl
price
payment
structur
reimburs
structur
physician
prescrib
decis
hypothes
influenc
drug
price
deviat
nhi
like
mani
health
insur
program
face
financi
challeng
expenditur
exceed
revenu
sinc
annual
pharmaceut
expenditur
doubl
billion
new
taiwan
dollar
nt
exchang
rate
nt
us
june
nt
billion
bnhi
pressur
control
outlay
stepwis
price
adjust
pa
aim
reduc
reimburs
price
close
market
trade
price
major
cost
contain
strategi
adopt
bnhi
sinc
earli
stage
price
adjust
reimburs
price
adjust
base
price
intern
product
interbrand
comparison
exist
product
april
bnhi
began
conduct
market
price
volum
survey
price
adjust
adjust
reimburs
price
individu
drug
accord
weight
averag
market
trade
price
wap
calcul
market
survey
wap
bnhi
allow
reason
profit
margin
known
reason
zone
rzone
physician
rzone
patent
drug
higher
offpat
drug
sinc
novemb
sinc
april
bnhi
adopt
differ
strategi
patent
offpat
drug
reimburs
price
patent
drug
still
adjust
base
individu
drug
wap
offpat
drug
adjust
accord
principl
gener
group
principl
drug
activ
ingredi
content
strength
group
togeth
reimburs
price
adjust
accord
group
weight
averag
price
gwap
calcul
market
trade
price
addit
file
provid
detail
pb
exampl
illustr
price
structur
price
adjust
base
market
price
volum
survey
gener
group
bnhi
perspect
demonstr
cost
save
pharmaceut
expenditur
pb
list
drug
liu
et
al
conclud
financi
incent
offer
drug
price
deviat
major
drive
forc
physician
switch
brand
drug
gener
version
howev
previou
studi
investig
potenti
switch
patent
offpat
drug
price
adjust
critic
analyz
whether
price
adjust
result
prescript
switch
product
whether
eventu
lead
anticip
cost
save
without
compromis
patient
safeti
therapeut
effect
acei
angiotensinconvert
enzym
inhibitor
arb
angiotensin
receptor
blocker
work
reninangiotensin
pathway
similar
effect
cardiovascular
diseas
renal
protect
sever
acei
launch
taiwan
offpat
product
heavili
domin
market
share
time
provid
ideal
exampl
obtain
knowledg
longitudin
chang
medic
util
expenditur
stepwis
price
adjust
furthermor
arb
gener
expens
acei
therapeut
similar
acei
abl
compar
impact
price
adjust
two
class
therefor
studi
use
acei
arb
exampl
examin
impact
taiwan
stepwis
price
adjust
util
expenditur
patent
offpat
drug
retrospect
observ
studi
base
cohort
patient
treat
acei
andor
arb
within
taiwan
nhi
program
longitudin
health
insur
databas
contain
origin
claim
data
one
million
beneficiari
randomli
sampl
year
registri
beneficiari
nation
health
insur
research
databas
nhird
contain
registr
data
everyon
beneficiari
nhi
program
period
januari
januari
bnhi
nation
health
research
institut
nhri
provid
access
regist
number
among
one
million
randomli
sampl
individu
clinic
condit
identifi
base
intern
classif
diseas
version
clinic
modif
code
acod
use
initi
taiwan
nhi
program
util
expenditur
drug
determin
inpati
outpati
servic
bnhicontract
health
set
pharmaci
patient
least
one
atc
code
acei
januari
decemb
arb
februari
decemb
includ
regard
whole
sampl
studi
defin
reninangiotensin
drug
user
patient
classifi
three
group
acei
user
use
acei
studi
period
arb
user
use
arb
studi
period
drug
user
use
least
one
acei
one
arb
concurr
subsequ
studi
period
year
preval
incid
user
acei
arb
drug
acei
arb
use
concurr
subsequ
given
year
overal
reninangiotensin
drug
acei
arb
use
alon
combin
given
year
calcul
acei
use
exampl
explain
mean
incid
preval
user
incid
acei
user
given
year
defin
patient
receiv
acei
first
time
year
drug
claim
acei
arb
alon
combin
preced
year
preval
acei
user
given
year
defin
patient
receiv
acei
year
date
birth
gender
clinic
condit
patient
retriev
analys
age
year
determin
earliest
date
acei
arb
prescript
presenc
cardiovascular
diseas
cvd
diabet
kidney
diseas
hyperlipidemia
determin
patient
least
one
code
individu
diseas
defin
daili
dose
ddd
use
repres
util
investig
agent
expenditur
express
nt
util
expenditur
acei
arb
express
month
show
longitudin
chang
time
seven
drug
price
adjust
examin
includ
one
base
market
price
volum
survey
impl
multivari
logist
regress
use
explor
differ
acei
user
arb
user
drug
user
odd
ratio
confid
interv
ci
calcul
boxtiao
intervent
analysi
appli
determin
whether
price
adjust
associ
signific
chang
util
expenditur
acei
arb
overal
reninangiotensin
drug
control
potenti
confound
factor
intervent
analysi
fit
independ
variabl
first
appli
autoregress
integr
movingaverag
arima
model
identif
process
residu
therefor
consid
follow
model
depend
variabl
ie
respons
seri
baselin
trend
denot
month
numer
order
sampl
size
n
number
price
adjust
studi
pa
level
indic
function
indic
whether
level
chang
ith
price
adjust
occur
assum
ith
price
adjust
occur
let
pa
tpa
trend
variabl
indic
whether
trend
chang
ith
price
adjust
occur
let
tpa
constant
term
describ
baselin
level
depend
variabl
describ
baselin
trend
first
intervent
occur
depict
level
chang
immedi
ith
price
adjust
depict
trend
chang
ith
price
adjust
ie
compar
monthli
trend
ith
price
adjust
monthli
trend
ith
price
adjust
b
backshift
oper
ie
b
x
x
b
b
p
b
p
autoregress
polynomi
model
b
b
q
b
q
move
averag
polynomi
white
nois
mean
varianc
depend
variabl
primari
analys
monthli
util
expenditur
acei
arb
overal
reninangiotensin
drug
subgroup
analys
monthli
util
expenditur
acei
categor
patent
drug
benazepril
cilazapril
imidapril
perindopril
ramipril
offpat
drug
captopril
offpat
enalapril
fosinopril
lisinopril
quinapril
offpat
offpat
acei
categor
origin
brand
gener
version
potenti
independ
variabl
includ
constant
baselin
level
baselin
trend
two
indic
variabl
price
adjust
name
level
chang
immedi
effect
trend
chang
longterm
effect
chang
time
three
confound
factor
one
three
confound
factor
global
budget
system
implement
taiwan
hospit
juli
increas
outpati
use
antidiabet
antihypertens
agent
increas
expenditur
pb
list
drug
two
confound
factor
chines
new
year
cni
outbreak
sever
acut
respiratori
syndrom
sar
decreas
expenditur
pb
list
drug
model
depend
variabl
remov
number
potenti
independ
variabl
repres
cutpoint
price
adjust
select
incorpor
model
socal
parsimoni
model
independ
variabl
initi
select
use
backward
elimin
procedur
collinear
diagnost
subsequ
perform
remov
variabl
condit
index
less
arima
model
express
factor
form
appli
residu
sever
candid
model
consid
accord
autocorrel
plot
partial
autocorrel
plot
model
minimum
akaik
inform
criterion
aic
valu
chosen
best
fit
ljungbox
chisquar
statist
reveal
insignific
autocorrel
residu
statist
analys
perform
use
sa
sa
cari
nc
pvalu
consid
signific
patient
met
inclus
criteria
identifi
acei
user
arb
user
drug
user
respect
tabl
among
patient
age
year
less
like
arb
user
drug
user
acei
user
male
patient
like
arb
user
acei
user
ci
less
like
drug
user
acei
user
ci
patient
hyperlipidemia
ci
like
take
arb
acei
patient
risk
cvd
ci
diabet
ci
kidney
diseas
ci
hyperlipidemia
ci
reveal
higher
likelihood
prescrib
drug
rather
acei
figur
number
cumul
incid
arb
user
given
year
alway
less
number
preval
arb
user
year
former
latter
figur
indic
annual
preval
arb
user
categori
cumul
incid
arb
user
also
includ
user
initi
use
acei
drug
preced
year
switch
arb
thereaft
baselin
level
util
acei
ddd
increas
ddd
p
per
month
januari
immedi
decreas
ddd
level
chang
p
implement
immedi
increas
ddd
level
chang
p
follow
acei
longterm
increas
trend
decreas
ddd
per
month
implement
trend
chang
p
turn
longterm
decreas
trend
ddd
per
month
implement
trend
chang
p
diminish
ddd
decemb
figur
tabl
subgroup
analys
observ
util
offpat
acei
show
similar
trend
acei
baselin
increas
trend
turn
downward
trend
even
earlier
follow
hand
util
patent
acei
show
increas
trend
throughout
studi
period
figur
tabl
offpat
acei
categor
origin
brand
gener
version
found
baselin
increas
trend
util
origin
brand
version
turn
decreas
trend
implement
gener
version
still
show
upward
trend
turn
downward
trend
afterward
implement
figur
tabl
unlik
acei
longterm
increas
trend
util
arb
overal
reninangiotensin
drug
observ
age
defin
earliest
date
acei
arb
prescript
clinic
condit
repres
code
adjust
odd
ratio
estim
multivari
logist
regress
refer
group
defin
patient
treat
acei
studi
period
patient
treat
arb
defin
arb
user
patient
treat
least
one
acei
one
arb
studi
period
defin
drug
user
signific
repres
p
p
acei
angiotensinconvert
enzym
inhibitor
arb
angiotensin
receptor
blocker
odd
ratio
sd
standard
deviat
respect
baselin
level
util
arb
zero
increas
ddd
p
per
month
februari
follow
longterm
increas
trend
use
arb
increas
ddd
per
month
trend
chang
p
implement
arb
longterm
increas
trend
increas
ddd
per
month
trend
chang
p
reach
ddd
decemb
baselin
level
util
overal
reninangiotensin
drug
ddd
util
show
longterm
increas
trend
ddd
p
per
month
januari
implement
overal
usag
experienc
immedi
decreas
ddd
level
chang
p
howev
throughout
studi
period
longterm
increas
trend
util
overal
reninangiotensin
drug
influenc
price
adjust
reach
ddd
decemb
figur
tabl
regard
three
confound
factor
cni
significantli
result
immedi
decreas
util
acei
includ
subgroup
analys
arb
overal
reninangiotensin
drug
tabl
baselin
level
expenditur
acei
nt
increas
nt
p
per
month
januari
expenditur
acei
experienc
immedi
decreas
nt
level
chang
p
nt
level
chang
p
respect
follow
longterm
increas
trend
acei
expenditur
turn
downward
trend
nt
per
month
implement
trend
chang
p
implement
acei
expenditur
show
immedi
decreas
nt
level
chang
p
maintain
longterm
tabl
subgroup
analys
observ
expenditur
offpat
acei
show
similar
trend
acei
overal
baselin
increas
trend
also
turn
decreas
trend
follow
experienc
addit
level
reduct
follow
hand
expenditur
patent
acei
show
increas
trend
throughout
studi
period
figur
tabl
offpat
acei
categor
origin
brand
gener
version
found
expenditur
offpat
origin
brand
acei
show
similar
trend
offpat
acei
expenditur
offpat
gener
acei
show
immedi
decreas
implement
influenc
price
adjust
long
term
figur
tabl
unlik
acei
expenditur
arb
reveal
longterm
increas
trend
baselin
level
expenditur
arb
zero
increas
trend
nt
p
per
month
februari
follow
longterm
increas
trend
expenditur
arb
increas
nt
per
month
trend
chang
p
implement
longterm
increas
trend
decreas
nt
per
month
trend
chang
p
follow
longterm
upward
trend
increas
nt
trend
chang
p
reach
nt
decemb
baselin
level
expenditur
overal
reninangiotensin
drug
nt
increas
trend
nt
p
per
month
januari
implement
longterm
increas
trend
increas
nt
per
month
trend
chang
p
figur
tabl
regard
three
confound
factor
cni
significantli
result
immedi
decreas
expenditur
acei
except
offpat
gener
acei
arb
overal
reninangiotensin
drug
tabl
tabl
impact
price
adjust
monthli
util
acei
arb
overal
reninangiotensin
drug
continu
factor
arima
model
repres
p
q
p
autoregress
order
differenc
order
q
movingaverag
order
season
order
repres
p
q
take
acei
exampl
movingaverag
oper
repres
q
mean
b
b
parsimoni
model
adopt
therefor
signific
independ
variabl
incorpor
model
two
major
find
studi
one
increas
preval
arb
user
associ
switch
acei
user
result
consist
longterm
trend
increas
util
arb
longterm
trend
decreas
util
acei
increas
expenditur
reninangiotensin
drug
throughout
studi
primarili
result
increas
number
incid
arb
user
potenti
switch
acei
arb
chang
use
overal
reninangiotensin
drug
ultim
cost
save
achiev
overal
use
reninangiotensin
drug
find
differ
previou
studi
show
cost
save
pharmaceut
expenditur
pb
list
drug
gener
substitut
driven
financi
incent
physician
price
adjust
mention
featur
taiwan
health
care
system
physician
prescrib
dispens
drug
permit
taiwan
depart
health
hire
pharmacist
work
onsit
pharmaci
physician
stand
profit
gap
reimburs
price
market
trade
price
liu
et
al
conduct
studi
taiwan
investig
prescrib
prefer
origin
brand
gener
drug
relat
potenti
profit
margin
found
prescrib
gener
increas
reimburs
price
decreas
result
consist
find
examin
chang
util
offpat
acei
observ
util
offpat
origin
brand
acei
lower
offpat
gener
acei
sinc
although
initi
upward
trend
use
offpat
gener
acei
turn
decreas
trend
implement
use
drug
still
higher
offpat
origin
brand
drug
howev
find
differ
liu
et
al
look
acei
arb
sinc
two
class
drug
work
reninangiotensin
pathway
similar
effect
cardiovascular
diseas
renal
protect
physician
make
prescrib
decis
acei
arb
patient
need
reninangiotensin
drug
observ
follow
initi
rise
trend
use
acei
turn
decreas
trend
primarili
due
decreas
use
offpat
acei
initi
rise
trend
use
arb
increas
follow
use
arb
exceed
acei
fact
profit
margin
patent
offpat
drug
vari
time
depend
drug
turn
patent
appli
wap
adjust
offpat
appli
gwap
adjust
well
valu
rzone
access
profit
margin
physician
impos
bnhi
extent
wap
adjust
patent
drug
smaller
gwap
adjust
offpat
drug
rzone
larger
patent
drug
offpat
drug
patent
drug
offer
higher
financi
incent
physician
stepwis
price
adjust
anoth
studi
conduct
lee
et
al
address
issu
taiwan
cost
contain
strategi
pharmaceut
expenditur
author
studi
also
appli
boxtiao
intervent
analysi
examin
level
chang
immedi
effect
implement
drug
price
adjust
found
pharmaceut
expenditur
pb
list
drug
significantli
decreas
introduct
price
adjust
base
gener
group
studi
includ
time
trend
variabl
model
enabl
us
investig
longterm
effect
price
adjust
fact
found
longterm
trend
expenditur
overal
reninangiotensin
drug
increas
explor
increas
expenditur
overal
reninangiotensin
drug
found
annual
incid
reninangiotensin
drug
user
declin
time
signific
trend
increas
found
util
reninangiotensin
drug
studi
period
also
found
annual
incid
arb
user
annual
preval
arb
user
increas
time
particular
annual
preval
arb
user
alway
exceed
number
cumul
incid
arb
user
indic
annual
preval
arb
user
categori
cumul
incid
arb
user
also
patient
ever
treat
acei
find
suggest
increas
expenditur
reninangiotensin
drug
throughout
studi
primarili
result
increas
number
incid
arb
user
potenti
switch
acei
arb
chang
use
overal
reninangiotensin
drug
although
health
care
system
canada
european
countri
differ
taiwan
refer
price
rp
scheme
adopt
countri
control
cost
demand
side
patient
provid
physician
side
studi
conduct
reveal
rp
scheme
longterm
effect
evid
netherland
show
implement
rp
scheme
cost
drug
cover
rp
scheme
increas
less
predict
cost
drug
outsid
rp
scheme
increas
annual
addit
evid
germani
hungari
show
pharmaceut
expenditur
still
well
control
volum
growth
occur
implement
rp
scheme
previou
studi
report
use
cheaper
gener
drug
may
lead
cost
save
clinic
concern
regard
patient
safeti
therapeut
effect
relat
treatment
discontinu
also
rais
studi
demonstr
prescript
switch
cheaper
drug
expens
agent
patient
complex
clinic
condit
like
treat
drug
subsequ
concurr
use
acei
arb
acei
alon
noteworthi
differ
arb
acei
may
persist
cough
caus
acei
patient
toler
acei
often
switch
arb
differ
clinic
recommend
arb
acei
note
studi
period
analys
warrant
compar
effect
econom
outcom
patient
treat
acei
treat
arb
switch
acei
arb
studi
sever
limit
first
baselin
diseas
sever
led
initi
treatment
acei
arb
compar
unabl
distinguish
clinic
appropri
stop
switch
drug
individu
patient
assess
clinic
condit
use
code
like
minim
potenti
bia
second
control
group
studi
price
adjust
implement
nationwid
concurr
howev
time
point
preintervent
period
serv
control
group
postintervent
period
intervent
analysi
thu
issu
regard
intern
valid
histori
matur
taken
consider
final
time
period
price
adjust
quit
short
incorpor
price
adjust
level
chang
trend
chang
intervent
model
would
show
sever
multicollinear
would
difficult
achiev
signific
collinear
paramet
previou
studi
examin
level
chang
trend
chang
howev
sinc
trend
chang
repres
longterm
effect
polici
intervent
implic
greater
level
chang
explain
ignor
therefor
adopt
parsimoni
model
instead
full
model
keep
signific
predictor
select
backward
elimin
procedur
collinear
diagnost
way
longterm
effect
price
adjust
examin
multicollinear
problem
avoid
implement
taiwan
stepwis
price
adjust
differ
adjust
strategi
appli
patent
offpat
drug
achiev
cost
save
offpat
acei
patent
acei
arb
overal
reninangiotensin
drug
long
term
increas
incid
arb
user
possibl
switch
acei
arb
emerg
result
indic
polici
maker
taiwan
reconsid
appropri
current
adjust
strategi
appli
patent
offpat
product
sinc
result
differ
profit
margin
physician
obtain
two
class
drug
affect
physician
prescrib
decis
addit
file
principl
taiwan
price
adjust
base
market
price
volum
survey
well
gener
group
file
describ
background
taiwan
pharmaceut
benefit
scheme
pb
delin
detail
process
stepwis
price
adjust
also
provid
exampl
show
lower
reimburs
price
decreas
profit
physician
